We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Test to Measure DNA Damage in Blood

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00523471
First Posted: August 31, 2007
Last Update Posted: February 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AHS Cancer Control Alberta
  Purpose
To check the radiosensitivity level in individual patients based on their DNA damage level.

Condition Intervention
Prostate Cancer Procedure: Blood test

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Gamma-H2AX as a Molecular Predictor of Prostate Cancer Radiosensitivity

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 40
Study Start Date: July 2007
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
community sample
Criteria

Inclusion Criteria:

  • prostate cancer diagnosis
  • undergoing radiotherapy
  • agree to participate in study

Exclusion Criteria:

  • not willing to participate
  • not undergoing radiotherapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00523471


Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Nadeem Pervez, MBBS, FRCPC AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00523471     History of Changes
Other Study ID Numbers: GU-6-0076/ethics 23586
First Submitted: August 30, 2007
First Posted: August 31, 2007
Last Update Posted: February 26, 2016
Last Verified: April 2012

Keywords provided by AHS Cancer Control Alberta:
prostate cancer
gamma H2AX
radiosensitivity

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases